Clinical observation of hepatic portal vein ligation (PVL) combined with apatinib and Camrelizumab transformation in the treatment of patients with primary hepatocellular carcinoma with residual liver volume
Latest Information Update: 27 Dec 2022
At a glance
- Drugs Camrelizumab (Primary) ; Rivoceranib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms PLACES
- 08 Nov 2022 Status changed to completed, as per results presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases.
- 08 Nov 2022 Results assessing the efficay and safety of hepatic portal vein ligation combined with Apatinib and Camrelizimabin conversion of HCC with insufficient FLR to resectable hepatocellular Carcinoma, presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases.
- 08 Jun 2021 Results (n=14) presented at the 57th Annual Meeting of the American Society of Clinical Oncology